The global microbial API market size is anticipated to reach USD 96.11 billion by 2030 and display a CAGR of 6.66% from 2023 to 2030, according to the report. The growth can be attributed to the rising demand for antibodies, proteins, small molecules, and related products capable of treating life-threatening diseases. Furthermore, an increase in R&D efforts for the manufacturing of innovative vaccines and combined therapy is anticipated to propel the market growth.
Microorganisms undergo fermentation for the development of secondary metabolites. Adjustments in growth environments are made to enable these organisms to covert economical carbon sources (starch, glucose, sucrose) and nitrogen sources (cotton-seed flour, soybean flour, peptone) into useful intermediates or microbial APIs (such as vitamins, antibiotics, amino acids). APIs are the biological/synthetic active constituents of pharmaceuticals and are used to treat, detect, mitigate, and prevent diseases, including conditions such as CNS disorders, diabetes, oncology, neurological diseases, cardiovascular and respiratory disorders, and others. Some of the production techniques used for the manufacture of API include chemical synthesis, recombinant DNA, fermentation, isolation, and natural source recovery.
There is high pricing pressure, increased competition, and declining pricing margins faced by pharma companies for small molecules and biologics that have lost exclusivity. APIs, which are the therapeutic core of every finished medicinal product, account for 30% of total drug product expenses for small molecules and up to 55% for biosimilar and generics. As a result, API manufacturers are always challenged to increase performance while lowering prices.
While microbial fermentation has been in existence for a long time, it offers pharmaceutical companies an efficient and cost-effective means to reduce production timelines. When combined with contemporary molecular biology techniques and genetic engineering tools, the fermentation process enhances the safety and efficacy of medicines. Rising initiatives for advancements in molecular biology and synthetic biology have had a profound effect on the development of innovative biosynthetic pathways. Moreover, microbial fermentation techniques find applications not only in the pharmaceutical industry but also in sectors such as food production, bio catalytic enzymes, agriculture, and various other fields.
Market players are undertaking strategic initiatives to address the growing demand for efficient and effective drug formulation manufacturing capacity. Players in the market are focusing on developing new products and acquisition of regional players to strengthen their position in the regional market. For instance, in March 2023, Cytovance Biologics entered into a partnership with Phenotypeca for the development of the saccharomyces cerevisiae strain. The partnership is expected to enhance biopharmaceutical manufacturing and improve biologics production efficiency. Such initiatives are expected to propel the overall growth of the microbial API market.
Microorganisms undergo fermentation for the development of secondary metabolites. Adjustments in growth environments are made to enable these organisms to covert economical carbon sources (starch, glucose, sucrose) and nitrogen sources (cotton-seed flour, soybean flour, peptone) into useful intermediates or microbial APIs (such as vitamins, antibiotics, amino acids). APIs are the biological/synthetic active constituents of pharmaceuticals and are used to treat, detect, mitigate, and prevent diseases, including conditions such as CNS disorders, diabetes, oncology, neurological diseases, cardiovascular and respiratory disorders, and others. Some of the production techniques used for the manufacture of API include chemical synthesis, recombinant DNA, fermentation, isolation, and natural source recovery.
There is high pricing pressure, increased competition, and declining pricing margins faced by pharma companies for small molecules and biologics that have lost exclusivity. APIs, which are the therapeutic core of every finished medicinal product, account for 30% of total drug product expenses for small molecules and up to 55% for biosimilar and generics. As a result, API manufacturers are always challenged to increase performance while lowering prices.
While microbial fermentation has been in existence for a long time, it offers pharmaceutical companies an efficient and cost-effective means to reduce production timelines. When combined with contemporary molecular biology techniques and genetic engineering tools, the fermentation process enhances the safety and efficacy of medicines. Rising initiatives for advancements in molecular biology and synthetic biology have had a profound effect on the development of innovative biosynthetic pathways. Moreover, microbial fermentation techniques find applications not only in the pharmaceutical industry but also in sectors such as food production, bio catalytic enzymes, agriculture, and various other fields.
Market players are undertaking strategic initiatives to address the growing demand for efficient and effective drug formulation manufacturing capacity. Players in the market are focusing on developing new products and acquisition of regional players to strengthen their position in the regional market. For instance, in March 2023, Cytovance Biologics entered into a partnership with Phenotypeca for the development of the saccharomyces cerevisiae strain. The partnership is expected to enhance biopharmaceutical manufacturing and improve biologics production efficiency. Such initiatives are expected to propel the overall growth of the microbial API market.
Microbial API Market Report Highlights
- Based on host, the mammalian segment dominated the market in 2022 and is expected to grow at the fastest CAGR over the forecast period, as microbial APIs are widely adopted due to their proven efficacy and safety profile for the development of therapeutic antibodies
- Based on type, the antibody segment held the dominant market share in 2022 due to the rising need to develop antibody-based therapeutics
- Based on site, the outsourced segment held the largest revenue share in 2022, owing to the rising adoption of CDMOs and CMOs for drug development
- Asia Pacific has established a strong regional position in the market for microbial API due to the presence of manufacturing facilities for high-quality APIs in the region
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends, & Scope
Chapter 4. Host Business Analysis
Chapter 5. Type Business Analysis
Chapter 6. Site Business Analysis
Chapter 7. End-use Business Analysis
Chapter 8. Molecule Business Analysis
Chapter 9. Regional Business Analysis
Chapter 10. Competitive Landscape
List of Tables
Companies Profiled
- MERCK & CO., INC.
- Topfond Pharmaceutical Co., Ltd.
- DSM
- CSPC Pharmaceutical Group Limited
- KOLON LIFE SCIENCE
- Shandong Lukang Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Lonza
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 180 |
| Published | November 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 58.04 Billion |
| Forecasted Market Value ( USD | $ 96.11 Billion |
| Compound Annual Growth Rate | 6.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
